VAL-083 a modern and unique cancer chemotherapy, being developed to treat glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, and other solid tumor indications.
Our mission is to benefit patients and create shareholder value by rapidly developing and commercializing anti-cancer therapies in orphan cancer indications where patients have failed or are unlikely to respond to modern therapy.
DelMar Pharmaceuticals is a clinical and commercial stage drug development company with a focus on the treatment of cancer. We are conducting clinical trials in the United States with our product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme (GBM).
DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting
SNO Poster: Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma
DelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015
DelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
DelMar Pharmaceuticals Collaborators Present Data on the Unique Molecular Mechanisms Responsible for VAL-083 Activity Against Cancer
DelMar Pharmaceuticals to Present Updated Phase II Safety and Efficacy Data on VAL-083 in Refractory Glioblastoma Multiforme
DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung
DelMar Pharmaceuticals to Present at the SeeThruEquity Microcap Investor Forum on November 12, 2015
VAL-083, our first product candidate, represents a "first-in-class" small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.Learn more about VAL-083
Our mission is to benefit patients and create shareholder value by rapidly developing and commercializing anti-cancer therapies in orphan cancer indications where patients have failed or are unlikely to respond to modern therapy.Learn more about DelMar
Our drug discovery research focuses on identifying well-validated clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan drug indications.Learn more about our drug development pipeline